fbpx

Psychedelic Medicine

Association

Psychedelic Medicine

Association

Excerpts from the publication

Methods: Participants were randomly assigned to a 52-minute intravenous administration of ketamine (0.71 mg/kg, N=17) or the active control midazolam (0.025 mg/kg, N=23), provided during the second week of a 5-week outpatient regimen of motivational enhancement therapy.

Results: Ketamine significantly increased the likelihood of abstinence, delayed the time to relapse, and reduced the likelihood of heavy drinking days compared with midazolam. Infusions were well tolerated, with no participants removed from the study as a result of adverse events.

Conclusions: A single ketamine infusion was found to improve measures of drinking in persons with alcohol dependence engaged in motivational enhancement therapy. These preliminary data suggest new directions in integrated pharmacotherapy-behavioral treatments for alcohol use disorder.

Read more

Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder

Davis, A,K., Barrett, F.S., Darrick G. May, D.G., Cosimano, M.P., Sepeda, N.D., Johnson, M.W., Finan, P.H., & Griffiths, R.R.
November 2020

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.

Stephen Ross, Anthony Bossis, Jeffrey Guss, Gabrielle Agin-Liebes, Tara Malone,Barry Cohen, Sarah E Mennenga, Alexander Belser, Krystallia Kalliontzi, James Babb, Zhe Su, Patricia Corby, and Brian L Schmidt
November 2016

Increases in Psychological Flexibility Mediate Relationship Between Acute Psychedelic Effects and Decreases in Racial Trauma Symptoms Among People of Color

Alan K. Davis, Yitong Xin, Nathan D. Sepeda, Albert Garcia-Romeu, Monnica T. Williams
August 2021

Psilocybin as a Novel Pharmacotherapy for Treatment-Refractory Anorexia Nervosa

Sarah-Catherine Rodan, Phillip Aouad, Iain S McGregor, Sarah Maguire
June 2021